Intravitreal injections continue to be one of the most commonly performed procedures by
ophthalmologists. Although the injections are generally well tolerated, sight-threatening …

Abstract Purpose of Review Intravitreal anti-vascular endothelial growth factor (VEGF)
agents are used routinely in the management of neovascular conditions including …

Ocular drug delivery remains the focus of much modern research. Primary routes of
administration include the surface, the intravitreal space, the subretinal space, and the …

Background Age-related macular degeneration (AMD) stands as the foremost cause of
irreversible central vision impairment, marked by choroidal neovascularization (CNV). The …

Pathological ocular neovascularization resulting from retinal ischemia constitutes a major
cause of vision loss. Current anti‐VEGF therapies rely on burdensome intravitreal injections …

Randomised clinical trials (RCTs) are generally considered the gold-standard for providing
scientific evidence for treatments' effectiveness and safety but their findings may not always …

Drug-related adverse effects of antivascular endothelial gro... : Current Opinion in Ophthalmology
Drug-related adverse effects of antivascular endothelial growth factor agents : Current Opinion …

Introduction Anti-angiogenesis therapy with intravitreal anti-VEGF agents is now the
standard-of-care treatment for myopic choroidal neovascularization (CNV). Areas covered …

Patient safety is a primary priority in the conduction of retinal gene therapy trials. An
understanding of risk factors and mitigation strategies for post-procedure complications is …

Purpose Currently, invasive monthly intravitreal injections through the eyeball are required
to deliver retinal drugs. Injections of oleogels into the vitreous have the potential for …